Brian W. Vogler

A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins

Stephen B. Keysar, David P. Astling, Ryan T. Anderson et al. · Molecular Oncology · 2013 · 164 citations · Full text

Hedgehog Signaling Alters Reliance on EGF Receptor Signaling and Mediates Anti-EGFR Therapeutic Resistance in Head and Neck Cancer

Stephen B. Keysar, Phuong N. Le, Ryan T. Anderson et al. · Cancer Research · 2013 · 94 citations · Full text

Neck Cancer, Egf Receptor Signaling, Pathology +18

Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies

Daniel W. Bowles, Jennifer R. Diamond, Elaine T. Lam et al. · Clinical Cancer Research · 2014 · 73 citations · Full text

Characterization of the Nannochloropsis gaditana storage carbohydrate: A 1,3-beta glucan with limited 1,6-branching

Brian W. Vogler, Jacob Brannum, Jeffrey W. Chung et al. · Algal Research · 2018 · 34 citations · Full text

Food Chemistry, 1,3-Beta Glucan, Bioorganic Chemistry +10

The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas

Ryan T. Anderson, Stephen B. Keysar, Daniel W. Bowles et al. · Molecular Cancer Therapeutics · 2013 · 31 citations · Full text

Pathology, Tumor Biology, Cancer-associated Virus +16